Xenikos B.V.

Xenikos announces first patient receives T-Guard(R) for steroid-refractory acute GVHD in pivotal U.S.-based Phase 3 trial

Xenikos presents promising new data from expanded access program (EAP) using T-Guard(R) to treat steroid-refractory acute GVHD at ASH Annual Meeting

Xenikos appoints Stanley Musial as Chief Financial Officer and Chief Business Officer

Xenikos receives FDA Fast Track designation for T-Guard(R) for treating steroid-refractory acute graft-versus-host disease

Xenikos announces IND clearance by the FDA for a pivotal Phase 3 trial using T-Guard(R) for treating steroid-refractory acute GVHD

Xenikos partners with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to conduct a U.S.-based Phase 3 trial to test T-Guard(R) in acute graft-versus-host disease

Xenikos B.V. : Final results from T-Guard(R) Phase 1/2 trial in steroid-resistant acute graft-versus-host disease published online in peer-reviewed journal Biology of Blood and Marrow Transplantation

Dutch Company Xenikos Secures USD 30 Million in Series B Financing

Xenikos announces data from phase I/II trial with T-Guard(TM) treatment of steroid-resistant acute GVHD presented at ASH Annual Meeting

Xenikos announces data from phase I/II trial with T-GuardTM for the treatment of steroid-resistant acute GVHD to be presented at ASH Annual Meeting

Xenikos to participate in BIO-Europe(R) 2017 – 23rd Annual International Partnering Conference

Xenikos to participate in BIO-Europe Spring(R) 2017 – 11th Annual International Partnering Conference

Xenikos awarded EUR 1 million innovation credit extension to support T-Guard(TM) development

Xenikos appoints Eric van Hooren as Chief Development Officer to drive forward T-Guard(TM) clinical development program

Xenikos to participate in BIO-Europe(R) 2016 – 22nd Annual International Partnering Conference

Xenikos B.V. to participate in 3PBio Forum technology transfer panel on September 29 at BIOSPAIN 2016

Xenikos B.V.: Last patient treated in Phase 1/2 trial with T-Guard(TM) in acute graft-versus-host disease

Xenikos B.V. to introduce immunotherapy T-Guard(TM) to potential pharmaceutical partners at BIO International Convention 2016